Skip to main content
graph.swiss
Xlife Sciences AG

Xlife Sciences AG

17.25 CHF-0.35 (-1.99%)
XSWX:XLSMarket Closed
ListedCHF99MHealthcareBiotechnology20 employees

Company Profile

Legal NameXlife Sciences AG
CEOMr. Oliver R. Baumann
HeadquartersTalacker 35
Phone41 44 385 84 60
Employees (FTE)20
SectorHealthcare
IndustryBiotechnology

Business Description

Xlife Sciences AG is a Switzerland-based publicly listed incubator and accelerator in the life sciences sector. It specializes in the value development and commercialization of promising early-stage research projects from universities and research institutions, bridging the gap between research and development and healthcare markets. The company focuses on four key areas: technology platforms, biotechnologies and therapies, medical technology including health technology, and artificial intelligence in digital health. Notable initiatives include identifying innovative biomarkers for kidney diseases, developing antibody-drug conjugates via click chemistry and microfluidic screening, and offering Neuromex, a screening tool for early detection of neurological diseases like Alzheimer's. Xlife Sciences AG also manufactures chemical and active pharmaceutical ingredients for human and veterinary medicines and provides clinical research organization services. Founded in 2019 and headquartered in Zurich, it supports researchers and entrepreneurs while emphasizing sustainability, such as minimizing animal testing and low-energy production processes. With around 17 employees, it plays a vital role in advancing solutions for unmet medical needs.

Profitability & Growth

Profitability

Profit Margin+3.39%
Operating Margin+280.04%
Return on Equity (TTM)-7.05%
Return on Assets (TTM)-3.73%

Recent Year-End

Revenue275.3K
Revenue / Share0.05
Gross Profit9.3K
EBITDA-3.3M
Diluted EPS-3.76
Revenue Growth YoY+6.65%

Balance Sheet Snapshot

Total Cash (MRQ)

1.1M

Total Debt (MRQ)

60.6M

Current Ratio (MRQ)

0.10

Book Value / Share

52.84

Stock Statistics

Shares Outstanding5.8M
Float Shares2.8M
Avg Volume (10d)6.1K
Avg Volume (90d)13.8K
% Held by Insiders+48.49%
% Held by Institutions+3.74%

Valuation

Market Cap99.5M
Enterprise Value245.7M
Trailing P/E5.37
Forward P/E-8.25
PEG Ratio-8.25
Price / Sales (TTM)364.52
Price / Book (MRQ)0.33
EV / Revenue892.49
EV / EBITDA-74.36

Price Summary

52-Week Low15.75
52-Week High26.80
50-Day MA21.31
200-Day MA21.41
Beta0.45

Dividends

Forward Div Rate0.01
Forward Div Yield+0.05%
Trailing Div Rate0.01
Ex-Dividend Date2022-09-22